TRACON

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer-targeted therapies. Our lead product candidate, envafolimab, is a PD-L1 antibody in development for the treatment of sarcoma. Our other product candidates include TRC102, a small molecule in Phase 2 clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody in Phase 1 testing being developed in collaboration with I-Mab Biopharma; and multiple bispecific antibody programs in preclinical development also being developed in collaboration with I-Mab Biopharma.